Phase I Trial of the Combination of Docetaxel, Prednisone, and Pasireotide in Metastatic Castrate-Resistant Prostate Cancer

The safety and efficacy of the additional use of the novel agent pasireotide with the standard regimen of docetaxel and prednisone was explored in patients with metastatic prostate cancer. The results showed tolerability and preliminary efficacy. The combination is worthy of future investigation in...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Clin Genitourin Cancer
Main Authors: Thakur, Manish K., Heilbrun, Lance, Dobson, Kimberlee, Boerner, Julie, Stark, Karri, Li, Jing, Smith, Daryn, Heath, Elisabeth, Fontana, Joseph, Vaishampayan, Ulka
Formato: Artigo
Idioma:Inglês
Publicado: 2018
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6136146/
https://ncbi.nlm.nih.gov/pubmed/29534939
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clgc.2018.01.019
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares